A top official at the US Food and Drug Administration has announced plans to overhaul the agency’s vaccine approval pathway, asserting that Covid-19 vaccines may have played a role in the deaths of several children. The comments came from Dr. Vinay Prasad, who serves as the FDA’s chief medical and scientific officer and oversees the Center for Biologics Evaluation and Research, in an internal memo circulated on Friday.
In the memo, Dr. Prasad claimed that “healthy young children, who already faced extremely low mortality risk from Covid-19, were pressured through school and workplace mandates to receive a vaccine that could, in rare cases, result in fatal outcomes.” He referenced an “initial review” of 96 reported deaths in which the FDA allegedly linked 10 to the Covid-19 vaccine. No further details, case information, or methodology were provided in the document.
Dr. Prasad also argued that Covid-19 “was never highly lethal for children” and described its impact on young people as similar to other common respiratory illnesses, many of which do not require annual vaccination. He emphasized that, while vaccines have historically prevented millions of deaths, any medical product carries risks when used inappropriately.
Planned Changes to Vaccine Oversight
According to Prasad, the internal analysis has prompted the FDA to pursue a more rigorous process for evaluating vaccines before they reach the public. The proposed framework would call for stronger evidence on both safety and real-world benefits. Some of the most significant adjustments include:
Stricter evidence standards for vaccines intended for pregnant women.
New requirements for pneumonia vaccine trials, shifting from antibody measurements to proof that the vaccine actually reduces illness.
A reassessment of the annual influenza vaccine model, including potential safety updates and changes to labeling.
Prasad suggested that these updates could involve larger clinical trials, which may extend approval timelines compared with the current system.
He also insisted that debate over the reforms should occur privately within the agency. The memo encouraged staff who fundamentally disagree with the proposed direction to consider stepping down.
Political and Public Health Context
The FDA and the Department of Health and Human Services did not comment publicly on the memo. However, the proposals reflect themes associated with HHS Secretary Robert F. Kennedy Jr., who has consistently questioned vaccine safety and long advocated for changes to federal vaccine policy. Kennedy previously led Children’s Health Defense, an organization known for its opposition to many vaccination practices.
Since assuming his role, Kennedy has reduced funding for mRNA vaccine development, dismissed all members of the CDC’s vaccine advisory committee, and instructed the CDC to revise parts of its website to include disproven claims linking vaccines to autism.
Upcoming Changes to Childhood Vaccine Recommendations
The CDC’s reshaped Advisory Committee on Immunization Practices—now appointed by Secretary Kennedy—is scheduled to meet next week. Agenda items include reviewing the timing of the hepatitis B vaccine for infants. For more than three decades, the first dose has been recommended shortly after birth, a policy credited with nearly eliminating childhood hepatitis B in the United States. Despite no new data concerning safety or effectiveness, the new committee is considering delaying the shot by months or years.
The proposed FDA reforms and ongoing policy shifts represent a dramatic departure from long-established vaccine practices, raising significant debate among public health experts and federal staff.
Leave a Reply